Hepatic Recompensation Before Systemic Therapy for Hepatocellular Carcinoma: BAVENO VII Criteria Still Needs to Be Updated [0.03%]
肝细胞癌系统治疗前的肝再功能性改善：BAVENO Ⅶ标准仍需更新
Federico Piñero,Margarita Anders,Leonardo da Fonseca et al.
Federico Piñero et al.
Proton Beam Therapy Boosts Outcomes of Atezolizumab/Bevacizumab in Advanced Hepatocellular Carcinoma: A Propensity Score Analysis [0.03%]
质子束治疗增强阿特珠单抗/贝伐珠单抗用于晚期肝细胞癌的疗效：倾向评分分析
Yuan-Hung Kuo,Wei Teng,Po-Ting Lin et al.
Yuan-Hung Kuo et al.
Introduction: Hepatocellular carcinoma (HCC) is a major cause of cancer-related mortality, particularly in patients with advanced stage. Atezolizumab plus bevacizumab (Ate/Bev) is the standard first-line therapy; however,...
Medical Management of Polycystic Liver Disease: A Position Statement From the European Reference Network on Hepatological Diseases [0.03%]
欧洲肝病参考网络关于多囊性肝病的医学管理立场声明
Sophia Heinrich,Andreia Margarida Carvalho de Matos,Jordi Colmenero et al.
Sophia Heinrich et al.
Polycystic liver disease (PLD) is a rare genetic disorder characterised by progressive liver enlargement due to multiple cysts. The main symptoms are liver volume-related. Although randomised controlled trials have shown that somatostatin a...
Clinical Features, Management and Prognosis of Hepatic Sarcoidosis: Insights From a Nationwide Italian Study [0.03%]
意大利全国性 sarcoidosis 肝脏损害的临床特点、治疗及预后特征研究
Cristina Della Corte,Daphne D&#x;Amato,Adele Rocchetti et al.
Cristina Della Corte et al.
Background and aims: Sarcoidosis is a rare systemic granulomatous disease involving the liver in up to 20% of cases. Data on hepatic sarcoidosis (HS) prevalence and management remain limited. This study aims to provide a ...
Exploring the Syndemic of Steatotic Liver Disease, Socioeconomic Inequities and Cancer Risk in the UK Biobank [0.03%]
探索英国生物银行中脂肪性肝病、社会经济不平等和癌症风险的 syndemic 现象
Lucia Dansero,Lorenzo Milani,Carlotta Sacerdote et al.
Lucia Dansero et al.
Background: Steatotic liver disease (SLD), formerly known as fatty liver disease, is associated with increased cancer risk. However, the impact of socioeconomic inequities remains understudied. This study investigates the...
Association of Epigenetic Aging Biomarkers With Risk of MASLD-Related HCC [0.03%]
表观遗传衰老生物标志物与MASLD相关肝细胞癌风险的关系
Alani Perkin,Sebastian M Armasu,Winnie Z Fan et al.
Alani Perkin et al.
Introduction: Hepatocellular carcinoma (HCC) development in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing health concern, but the underlying mechanisms are not fully understoo...
Reassessing Patient Selection and Clinical Endpoints in Terlipressin Therapy for HRS-AKI [0.03%]
重新评估特利普雷斯治疗HRS-AKI的患者选择和临床终点
Jianling Yu,Junbin Yan
Jianling Yu
Efficacy and Safety of Atezolizumab Plus Bevacizumab for Patients With Hepatocellular Carcinoma and Child-Pugh Class B [0.03%]
阿特朱单抗联合贝伐珠单抗治疗Child-Pugh B级肝细胞癌患者的疗效和安全性
Ryu Sasaki,Shigeo Shimose,Issei Saeki et al.
Ryu Sasaki et al.
Background & aims: Despite the advances in systemic therapy for unresectable hepatocellular carcinoma (HCC), patients with Child-Pugh class B (CP-B) liver function face a significant unmet need. This study evaluated the e...
Free Testosterone Is Associated With Worse Survival in Patients With Advanced Chronic Liver Disease Awaiting Liver Transplantation [0.03%]
血清游离睾酮水平与终末期肝病等待肝移植患者生存率的关系
Miguel Sogbe,Brittany Bromfield,Roberto Tellez et al.
Miguel Sogbe et al.
Background and aims: Hypogonadism is frequent in AdvCLD and associated with frailty and poor outcomes. This study aimed to evaluate the association between free testosterone (FT) levels and all-cause mortality in male pat...